New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2012
16:16 EDTNSRGY, MYGN, AZN, TRGT, TSL, STP, YGE, TIF, RIO, BHPOn The Fly: Closing Wrap
Stocks on Wall Street were lower on concerns of slowing growth in China. The futures barely reacted to February U.S. housing data, which showed starts were lower than expected but building permits were higher. The futures action led to a lower open for the broader market. The averages found a level in the first 30 minutes of trading where they sat and eventually began to drift higher. The market moved generally higher until the last hour of the session but the averages were never able to retake the baseline to continue their six day winning streak... ECONOMIC EVENTS: In the U.S., homebuilders began construction on a seasonally adjusted annual rate of 698,000 homes in February, down 1.1% from a month ago. Building permits jumped 5.1%, versus expectations for an increase of 0.6%. In China, a report said that home prices dropped in 45 Chinese cities last month and the country increased its gas and diesel prices for the second time in less than six weeks... MARKET NEWS: BHP Billiton (BHP) was widely quoted as stating that Chinese iron ore demand growth was "flattening," but the company came out and said that the slowdown had been discussed before and was not new information. Also, both BHP and rival Rio Tinto (RIO) confirmed plans to expand production in China even further. Still, BHP's confirmation along with other signals of a slowdown in China was attributed as a significant catalyst for today's market pull-back... Saudi Arabia said it is ready to meet any shortfalls in global oil supplies which, along with China's news, caused oil prices to fall 2%, weighing on the Energy sector of the S&P... Amazon.com (AMZN) moved up 3.67% following its $775M purchase of Kiva Systems, a maker of robots and other material handling technology... MAJOR MOVERS: Among the notable gainers was Tiffany (TIF), up $4.59, or 6.68%, to $73.27, after its earnings missed expectations but its FY12 guidance beat the Street's view. Also higher were a number of Chinese solar companies, including Yingli Green Energy (YGE), up 46c, or 12.07%, to $4.27, Suntech (STP), up 44c, or 14.06%, to $3.57, and Trina Solar (TSL), up 61c, or 7.85%, to $8.38, following the U.S. Commerce Department's decision to impose tariffs of less than 5% on the companies, which was well below the 20% to 30% that was forecast by some analysts. Noteworthy losers included Targacept (TRGT), down $2.22, or 29.96%, to $5.19, after it abandoned plans to seek approval for a depression drug it was developing in partnership with AstraZeneca (AZN), and Myriad Genetics (MYGN), down $1.33, or 5.19%, to $24.31, after the Supreme Court ruled that two patents held by Nestle (NSRGY) for certain personalized medicine products are invalid because the patents utilize "laws of nature" without adding significant additional features to those laws... INDICES: The Dow fell 68.94, or 0.52%, to 13,170.19; the Nasdaq lost 4.17, or 0.14%, to 3,074.15; and the S&P 500 dropped 4.23, or 0.30%, to 1,405.52.
News For BHP;RIO;TIF;YGE;STP;TSL;TRGT;AZN;MYGN;NSRGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 27, 2014
07:28 EDTBHPBHP Billiton says could sell Fayetteville shale gas assets
BHP CEO Andrew Mackenzie said in a statement, "As we look to improve the balance of liquids and gas across our Petroleum portfolio we have initiated the marketing our Fayetteville acreage. However, we will only divest the field if it maximizes value for shareholders."
07:22 EDTAZNAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
07:14 EDTMYGNMyriad Genetics announces inclusion of Prolaris test on NCCN Guidelines
Myriad Genetics announced that its Prolaris test has been included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, or NCCN Guidelines, for all men with localized prostate cancer, regardless of their risk category. The NCCN guidelines provide treatment recommendations to ensure that patients receive diagnostic treatment and services that are likely to improve clinical outcomes. Specifically, the updated NCCN guidelines include the use of the Prolaris test to help patients better assess their risk of disease specific mortality and biochemical recurrence. Importantly, Prolaris is supported by seven peer-reviewed publications and is the first and only genetic test for prostate cancer that is: Proven and validated based on gold standard clinical endpoints of disease recurrence and prostate cancer-specific death in untreated men, thus identifying men who can safely forgo initial surgery or radiation and be managed with active surveillance; Proven in clinical utility studies to change treatment recommendations for up to 65% of prostate cancer patients in all risk categories, which may enhance adherence to recommended treatments; and to receive a draft local coverage determination, or LCD, for Medicare reimbursement for low-risk patients.
October 24, 2014
09:05 EDTMYGNMyriad Genetics establishes tumor BRACAnalysis CDx lab in Europe
Myriad Genetics, announced it has established a Tumor BRACAnalysis CDx laboratory in Europe. Myriad's next-generation Tumor BRACAnalysis CDx test is a companion diagnostic that will identify up to 50% more patients with BRAC mutations who may benefit from treatment with PARP inhibitors, such as olaparib, compared to conventional germline testing alone. Olaparib is a novel PARP inhibitor being developed by AstraZeneca. Earlier today, the European Medicines Agency's, or EMA, Committee for Medicinal Products for Human Use, or CHMP, recommended marketing authorization for olaparib as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated, or germline and/or somatic, high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy. It is estimated that more than 22% of all ovarian cancer patients carry a deleterious germline or somatic mutation in the BRCA1 or BRCA2 genes and may benefit from olaparib therapy.
06:49 EDTAZNPfizer repurchase could squash AstraZeneca bid goal, Reuters says
Subscribe for More Information
06:38 EDTTSL, YGEEU sets emissions, renewable energy targets, NY Times says
Subscribe for More Information
October 23, 2014
06:27 EDTRIORio Tinto extends tenure of CEO Sam Walsh, CFO Chris Lynch
Subscribe for More Information
October 22, 2014
09:53 EDTTSLCredit Suisse Events at Solar Power International
Credit Suisse holds meetings in Las Vegas in conjunction with the Solar Power International Conference include ENPH, TSL, CSIQ, SCTY, JASO, HSOL and STRI on October 22.
07:35 EDTAZNCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 21, 2014
17:58 EDTBHPBHP Billiton Q1 iron-ore output up 17% YoY to 57.09 tons
17:56 EDTBHPBHP Billiton Q1 copper output down 3% YoY to 389,400 tons
Subscribe for More Information
10:00 EDTBHPOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AbbVie (ABBV) downgraded to Neutral from Buy at Guggenheim... BHP Billiton (BHP) downgraded to Hold from Buy at Jefferies... Bank of Marin (BMRC) downgraded to Market Perform from Outperform at Keefe Bruyette... Cobalt (CIE) downgraded to Speculative Buy from Buy at Global Hunter... Consolidated Edison (ED) downgraded to Underweight at Morgan Stanley... Deutsche Post (DPSGY) downgraded to Hold from Buy at Deutsche Bank... HCP (HCP) downgraded to Hold from Buy at Jefferies... IBM (IBM) downgraded to Hold from Buy at Evercore... Inland Real Estate (IRC) downgraded to Underperform from Neutral at BofA/Merrill... PerkinElmer (PKI) downgraded to Neutral from Buy at Janney Capital... Philips (PHG) downgraded to Neutral at UBS... QEP Midstream Partners (QEPM) downgraded to Market Perform at Wells Fargo... Rent-A-Center (RCII) downgraded to Market Perform from Outperform at Raymond James... Rhino Resources (RNO) downgraded to Underperform from Market Perform at Raymond James... Universal Forest (UFPI) downgraded to Neutral from Buy at Sterne Agee.
07:15 EDTAZNFDA to hold workshop on breast cancer drug development
Subscribe for More Information
06:11 EDTYGEYingli Green Energy surpasses 2,000 MW of solar panel deliveries in Americas
Yingli Green Energy announced that it has surpassed two gigawatts of cumulative solar panel deliveries in the Americas. The more than 6M Yingli Solar panels delivered are now generating electricity for more than 85,000 solar projects across the region. Yingli estimates that more than 80,000 homes and 5,000 business and institutions in the Americas are energized by its high-quality solar panels. Its most popular product line, the YGE 60 Cell Series, is a versatile multicyrstalline solar panel suited for most solar applications, from off-grid systems to large-scale utility projects. Since early 2013, Yingli has deployed more than 150 megawatts of its high-performing solar panels Latin America and the Caribbean, becoming a leader in the region in fewer than six quarters.
06:10 EDTAZNInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.
05:31 EDTBHPBHP Billiton downgraded to Hold from Buy at Jefferies
Jefferies downgraded BHP Billiton to Hold saying it sees limited near-term upside after cutting its commodities price estimates.
October 20, 2014
08:14 EDTTSLTrina Solar management to meet with Deutsche Bank
Subscribe for More Information
07:47 EDTAZNPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:19 EDTAZNIBC Life Sciences to hold a conference
Subscribe for More Information
07:14 EDTAZNEuropean College of Neuropsychopharmacology to hold a conference
27th ECNP Congress is being held in Berlin, Germany on October 18-21.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use